HongZhang BeijingChina

Wcn26 Post edited Speaker Card

https://storage.unitedwebnetwork.com/files/486/777412-35623-Hong Zhang_363132.png

Time	Session

09:25 10:55	B Cell Targeting in Glomerular Disease SK YusukeSuzuki Moderator Japan A Role for Kidney Resident B/plasma Cells in Kidney Disease Progression? HeatherReich Speaker heather.reich@uhn.caCanada B Cell Activating Factor and A Proliferation-inducing Ligand Signaling in Glomerular Disease HongZhang Speaker China B Cell Targeted Therapies in Glomerular Diseases RichardLafayette Speaker czar@stanford.eduUnited States The Future of B Cell Therapies in the Treatment of Glomerular Diseases Jonathan Barratt Speaker jb81@leicester.ac.ukUnited Kingdom Q&A Session 503
17:00 18:00	Industry Symposium 26 YusukeSuzuki Moderator Japan Evolving Landscape of IgA Nephropathy in 2026 and Beyond HongZhang Speaker China 303

Time	Session

12:50 13:50	Industry Symposium 47 BradRovin Moderator rovin.1@osu.eduUnited States Intro + IgAN Case: Global Perspective BradRovin Speaker rovin.1@osu.eduUnited States IgAN Case: China Perspective HongZhang Speaker China IgAN Case: Japan Perspective HITOSHISUZUKI Speaker Japan 301 - 302
14:10 15:10	Hot Debate: Complement Inhibition vs Nefecon in IgA Nephropathy – Which First for Patients at Risk? BKH Magdalena Madero Moderator madero.magdalena@gmail.comMexico Complement Inhibition Should Be Considered Before Nefecon in Patients With IgAN at Risk of Progression VladoPerkovic Speaker Australia Nefecon Should Be Considered Before Complement Inhibition in Patients With IgAN at Risk of Progression HongZhang Speaker China 501 - 502